arrow
L

Lauren Wilson

Moderna, Inc.
H指数:23
被引数:2,342

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

Goswami, J.; Cardona, J.F.; Caso, J.; Hsu, D.C.; Simorellis, A.K.; Wilson, L.; Dhar, R.; Wang, X.; Kapoor, A.; Collins, A.; 等. mRNA-1345的再次接种安全性、耐受性及免疫原性研究,该疫苗为针对RSV的mRNA疫苗,在≥50岁成人中初次接种12个月后进行再次接种。Clin. Infect. Dis. 2025, 23, ciaf515. [Google Scholar] [CrossRef]

2025-09-240
OAAI
Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

基于mRNA的RSV疫苗的安全性和免疫原性,包括在健康老年人的1期临床试验中进行12个月的加强

2024-02-2216
OAAI
Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

在1期临床试验中,基于mRNA的呼吸道合胞病毒疫苗在健康年轻人中的安全性,耐受性和免疫原性

2024-01-319
OAAI
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults

基于mRNA的RSV PreF疫苗在老年人中的功效和安全性

2023-12-1491
OA
Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study
2023-02-0622
OA